[go: up one dir, main page]

BRPI0511305A - método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1 - Google Patents

método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1

Info

Publication number
BRPI0511305A
BRPI0511305A BRPI0511305-9A BRPI0511305A BRPI0511305A BR PI0511305 A BRPI0511305 A BR PI0511305A BR PI0511305 A BRPI0511305 A BR PI0511305A BR PI0511305 A BRPI0511305 A BR PI0511305A
Authority
BR
Brazil
Prior art keywords
lfa
antagonist
annular
relieving
manufactured article
Prior art date
Application number
BRPI0511305-9A
Other languages
English (en)
Inventor
Bernard S Goffe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0511305A publication Critical patent/BRPI0511305A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODO DE ALIVIAR UM GRANULOMA ANULAR OU SARCóIDE, ARTIGO MANUFATURADO E USO DE UM ANTAGONISTA DE LFA-1. A presente invenção refere-se a um método de aliviar o granuloma anular ou doença sarcóide administrando a um paciente que tem a doença, uma quantidade terapeuticamente eficaz de um antagonista de LFA 1.
BRPI0511305-9A 2004-06-09 2005-06-08 método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1 BRPI0511305A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57876804P 2004-06-09 2004-06-09
US57909604P 2004-06-10 2004-06-10
PCT/US2005/020342 WO2005123777A2 (en) 2004-06-09 2005-06-08 Method of treating granuloma annulare or sarcoid

Publications (1)

Publication Number Publication Date
BRPI0511305A true BRPI0511305A (pt) 2007-12-04

Family

ID=35355731

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511305-9A BRPI0511305A (pt) 2004-06-09 2005-06-08 método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1

Country Status (11)

Country Link
US (1) US7396530B2 (pt)
EP (1) EP1756163A2 (pt)
JP (1) JP2008507592A (pt)
AU (1) AU2005254980A1 (pt)
BR (1) BRPI0511305A (pt)
CA (1) CA2568570A1 (pt)
IL (1) IL179557A0 (pt)
MX (1) MXPA06014354A (pt)
NO (1) NO20070127L (pt)
RU (1) RU2006146939A (pt)
WO (1) WO2005123777A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
CN102056485A (zh) * 2008-04-15 2011-05-11 萨可德公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
KR102134088B1 (ko) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
RU2671516C1 (ru) * 2018-01-10 2018-11-01 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия имени С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ лечения кольцевидной гранулемы

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002869A (en) 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
US5071964A (en) 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
NO900155L (no) 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
EP0462184A4 (en) 1989-03-09 1992-01-08 Dana Farber Cancer Institute Method of treating viral infections using lfa-1
ES2097747T3 (es) 1989-03-09 1997-04-16 Blood Res Center Molecula de adhesion intercelular 2 y sus ligandos de union.
AU5568290A (en) 1989-04-28 1990-11-29 Baylor College Of Medicine Method of suppressing hiv infection
DK0432249T3 (da) 1989-06-02 1997-02-17 Univ Johns Hopkins Med Monoklonale antistoffer over for beta-kæden i leukocytadhæsionsreceptoren, fremgangsmåder til fremstilling af disse antistoffer og anvendelse heraf
US5324510A (en) 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991018011A1 (en) 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
HUT69725A (en) 1991-10-01 1995-09-28 Gen Hospital Corp Process for producing compositions for preventing allograft rejection
JP3679112B2 (ja) 1991-10-04 2005-08-03 アメリカ合衆国 細胞接着分子の遮断による眼の炎症の治療
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB2266664A (en) 1992-04-28 1993-11-10 Pierre Francois Piguet Monoclonal antibodies for prophylaxis and treatment of pulmonary fibrosis
DK0656789T3 (da) 1992-08-21 1998-08-24 Genentech Inc Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
ATE267257T1 (de) * 1996-11-27 2004-06-15 Genentech Inc Humanisierte anti-koerper gegen cd11a
FR2763072B1 (fr) 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
PE20020420A1 (es) * 2000-10-02 2002-06-27 Novartis Ag Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1)

Also Published As

Publication number Publication date
AU2005254980A1 (en) 2005-12-29
US20060013818A1 (en) 2006-01-19
JP2008507592A (ja) 2008-03-13
US7396530B2 (en) 2008-07-08
CA2568570A1 (en) 2005-12-29
IL179557A0 (en) 2007-05-15
EP1756163A2 (en) 2007-02-28
NO20070127L (no) 2007-01-08
WO2005123777A2 (en) 2005-12-29
RU2006146939A (ru) 2008-07-20
WO2005123777A3 (en) 2006-03-02
MXPA06014354A (es) 2007-02-19

Similar Documents

Publication Publication Date Title
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0411295A (pt) compostos e seu uso na terapia
BR0314052A (pt) Imidazolpiridinas e métodos para sua fabricação e uso
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0519242A2 (pt) uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BRPI0410503B8 (pt) composição tópica e uso da composição
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
SE0001899D0 (sv) New compounds
TW200716208A (en) Modified and immediate release memantine bead formulation
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
WO2020023530A3 (en) Methods of treatment and prevention of alzheimer's disease
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.